GAITHERSBURG, MARYLAND, October 30, 2017 – Adaptive Phage Therapeutics, Inc. (APT) a clinical-stage company founded to provide an effective therapeutic response to the global rise of multi-drug resistant (MDR) pathogenic bacteria, announced the opening of their state-of-the-art BSL2 labs and phage manufacturing facilities designed to FDA GMP ICH Q7A and ISO Class 5 standards. The 7,200-square foot facility is strategically located in Gaithersburg, Maryland – within 25 miles of FDA, BDRD, NMRC, Walter Reed Military Hospital, Johns Hopkins, and NIH. APT’s facilities are unique as they were designed from the ground up specifically for manufacturing patient specific therapeutic phage products. In 2016, APT entered into a collaborative research and development agreement (CRADA) with the Naval Medical Research Center (NMRC) and has negotiated worldwide exclusive rights to NMRC’s innovative system for phage/pathogen rapid matching (patents pending), as well as proprietary datasets, and PhageBank®.
“Thank you to all who attended the ribbon cutting event for our new space in Gaithersburg”, said Greg Merrill, Adaptive Phage Therapeutics CEO. “This is another important milestone in the growth of adaptive phage Therapeutics and we appreciate the support we have received from all of our stakeholders.”
About Adaptive Phage Therapeutics, Inc.
Adaptive Phage Therapeutics, Inc. (APT) is a clinical-stage company founded to provide an effective therapeutic response to the global rise of multi-drug resistant (MDR) pathogenic bacteria. In 2016, APT entered into a collaborative research and development agreement (CRADA) with the Naval Medical Research Center (NMRC) and has negotiated worldwide exclusive rights to NMRC’s innovative system for phage/pathogen rapid matching (patents pending), as well as proprietary datasets, and PhageBank™. Learn more at http://www.aphage.com/